EA201991924A1 - THERAPEUTIC DENDRIMERS - Google Patents

THERAPEUTIC DENDRIMERS

Info

Publication number
EA201991924A1
EA201991924A1 EA201991924A EA201991924A EA201991924A1 EA 201991924 A1 EA201991924 A1 EA 201991924A1 EA 201991924 A EA201991924 A EA 201991924A EA 201991924 A EA201991924 A EA 201991924A EA 201991924 A1 EA201991924 A1 EA 201991924A1
Authority
EA
Eurasian Patent Office
Prior art keywords
dendrimers
therapeutic
formula
disclosed
dendrimer
Prior art date
Application number
EA201991924A
Other languages
Russian (ru)
Inventor
Уилльям Маккоулл
Мэриэнн Бернис Эшфорд
Иэн Грант
Эдвард Джон Хэннесси
Джон Пол Секрист
Дэвид Оуэн
Брайен Келли
Майкл Джианнис
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб filed Critical Астразенека Аб
Priority claimed from PCT/EP2018/054420 external-priority patent/WO2018154004A1/en
Publication of EA201991924A1 publication Critical patent/EA201991924A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/641—Branched, dendritic or hypercomb peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/40—Polyamides containing oxygen in the form of ether groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/003—Dendrimers

Abstract

Раскрыты дендримеры формулы (I)и их фармацевтически приемлемые соли. Также раскрыты фармацевтические композиции, содержащие дендример формулы (I), и способы их применения для лечения рака.Dendrimers of formula (I) and their pharmaceutically acceptable salts are disclosed. Also disclosed are pharmaceutical compositions containing a dendrimer of formula (I) and methods for their use in treating cancer.

EA201991924A 2017-11-29 2018-02-22 THERAPEUTIC DENDRIMERS EA201991924A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762591823P 2017-11-29 2017-11-29
PCT/EP2018/054420 WO2018154004A1 (en) 2017-02-22 2018-02-22 Therapeutic dendrimers

Publications (1)

Publication Number Publication Date
EA201991924A1 true EA201991924A1 (en) 2020-02-20

Family

ID=69636687

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991924A EA201991924A1 (en) 2017-11-29 2018-02-22 THERAPEUTIC DENDRIMERS

Country Status (1)

Country Link
EA (1) EA201991924A1 (en)

Similar Documents

Publication Publication Date Title
PH12019501896A1 (en) Therapeutic dendrimers
CY1124239T1 (en) AMINO-TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
CY1121858T1 (en) ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS CONTAINING THEM AND METHODS OF USING THEM
CY1122966T1 (en) 5-BROMO-2,6-DI-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE FOR USE IN THE THERAPEUTIC TREATMENT OF CANCER
CY1120866T1 (en) DNA-PK INHIBITORS
CY1121062T1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ALZHEIMER DISEASE
CY1122566T1 (en) 6,7,8,9-TETPAYDP-3H-PYRAZOLO[4,3-F]ISOQUINOLINE DERIVATIVE USEFUL IN THE THERAPEUTIC TREATMENT OF CANCER
EA201790078A1 (en) MNK INHIBITORS AND RELATED METHODS
CY1123059T1 (en) A1 RECEPTOR TRANSIENT ION CHANNEL INHIBITION
CY1123627T1 (en) DIHYDROIMIDAZOPYZINONE DERIVATIVES USEFUL IN THE THERAPEUTIC TREATMENT OF CANCER
EA201892075A1 (en) COMBINATION OF LSD1 INHIBITORS FOR USE FOR THE TREATMENT OF SOLID TUMORS
CY1119939T1 (en) 2,3-Dihydro-Benzo [1,4] Oxazine Derivative and Related Compounds such as Phosphoinositin-3-Kinase (R3K) Inhibitors for Therapeutic Therapy
EA201692487A1 (en) PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS
CY1126109T1 (en) TRPC6 INHIBITORS
CY1124243T1 (en) INHIBITING THE A1 TRANSIENT POTENTIAL RECEPTOR ION CHANNEL
EA201791516A1 (en) METHODS OF COMBINED TREATMENT OF MALIGNANT TUMORS
EA201591145A1 (en) Inhibitors of histonedehylase
EA201592068A1 (en) INHANSER INHIBITORS ZESTE HOMOLOGIST 2
EA201692513A1 (en) INHIBITORS OF LYSINE-SPECIFIC DEMETILASE-1
CY1122763T1 (en) NEW IMIDAZOPYRIDAZINE COMPOUNDS AND THEIR USE
EA202192905A1 (en) COMPOUNDS CONTAINING N-METHYL-2-PYRIDONE AND PHARMACEUTICALLY ACCEPTABLE SALTS
EA201692481A1 (en) COMBINATION CONTAINING GLUCOCORTICOID AND EDO-S101
CY1122357T1 (en) ANTI-CANCER COMBINATION INCLUDING CABAZITAXEL AND cisplatin
EA201790830A1 (en) ALDOSTERONSYNTASE INHIBITORS
EA201790253A1 (en) ALDOSTERONSYNTASE INHIBITORS